Specific to patients with muscle invasive bladder cancer, improvement in disease free survival was also observed with nivolumab versus placebo in all randomized patients (HR 0.66, 95% CI 0.53-0.81) ...

Adjuvant therapy with nivolumab (Opdivo, “nivo”) continues to show disease-free survival (DFS) and overall survival (OS) benefits compared with placebo among patients with muscle-invasive bladder ...

Adjuvant nivolumab (Opdivo) continued to show benefits in disease-free survival (DFS) compared with placebo in patients with muscle-invasive urothelial carcinoma (MIUC) who underwent radical surgery, ...

The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's ...

Investigators conducted a network meta-analysis of phase 3 trials on MIBC treatments to provide comparative ranking of perioperative therapies.

The FDA approval of nivolumab plus cisplatin and gemcitabine marks the first concurrent immunotherapy-chemotherapy combination for the population. The trial showed the combination significantly ...

Muscle-invasive bladder cancer patients who are ineligible or refuse cisplatin chemotherapy see “dramatic” improvements in ...

The FDA approved the PD-1 immune checkpoint inhibitor nivolumab (Opdivo) in combination with cisplatin and gemcitabine for the first-line treatment of adults with unresectable or metastatic urothelial ...

Early results from a single-arm phase II study suggest that use of an immune checkpoint inhibitor (ICI) combined with taxane chemotherapy could expand the therapeutic options for patients with ...

Testing for tumour DNA in the blood can successfully identify advanced bladder cancer patients who will not relapse following surgery, new research shows. This could allow doctors to target treatments ...

Petros Grivas, MD, PhD, discusses the overall survival and quality-of-life findings from the JAVELIN Bladder 100 trial of avelumab as maintenance therapy for advanced bladder cancer.

Credit: Thinkstock Investigators conducted a network meta-analysis of phase 3 trials on MIBC treatments to provide comparative ranking of perioperative therapies. Findings from studies over 30 years ...